Keyphrases
Type 1 Diabetes Mellitus (T1DM)
100%
Conventional Treatment
100%
Randomized Controlled Study
100%
Type I Diabetes
100%
Advanced Hybrid Closed Loop
100%
Hybrid Closed-loop Therapy
100%
Insulin
90%
Multiple Daily Injections
90%
Intermittently Scanned Continuous Glucose Monitoring (isCGM)
80%
Hemoglobin A1c (HbA1c)
40%
Serious Adverse Events
40%
Loop Groups
30%
Diabetic Ketoacidosis
20%
Severe Hypoglycemic Event
20%
Glucose Control
10%
Adult Population
10%
France
10%
European Countries
10%
Randomized Controlled Trial
10%
Germany
10%
Non-serious
10%
Intention-to-treat
10%
Breast Cancer
10%
Difference in Mean
10%
Glucose Level
10%
Glycemic Control
10%
Random Effects Model
10%
Change from Baseline
10%
Severe Hypoglycemia
10%
Between-group Difference
10%
Device-independent
10%
Randomized Methods
10%
Safety Endpoints
10%
Medtronic
10%
Intravitreous
10%
Continuous Glucose Monitoring
10%
Real-time Continuous Glucose Monitoring (rtCGM)
10%
Block Randomization
10%
International Trading
10%
Medicine and Dentistry
Insulin Dependent Diabetes Mellitus
100%
Hemoglobin A1c
66%
Adverse Event
66%
Arm
50%
Antidiabetic Agent
33%
Diabetic Ketoacidosis
33%
Intention-to-Treat Analysis
16%
Randomized Controlled Trial
16%
Hypoglycemia
16%
Clinician
16%
Bleeding
16%
Breast Cancer
16%
Random Effects Model
16%
Glycemic Control
16%
Nursing and Health Professions
Insulin Dependent Diabetes Mellitus
100%
Continuous Glucose Monitoring
100%
Adverse Event
40%
Hemoglobin A1c
40%
Antidiabetic Agent
20%
Diabetic Ketoacidosis
20%
Randomization
10%
Intention to Treat Analysis
10%
Clinician
10%
Bleeding
10%
Breast Cancer
10%
Hypoglycemia
10%
Glucose Level
10%
Pharmacology, Toxicology and Pharmaceutical Science
Insulin Dependent Diabetes Mellitus
100%
Hemoglobin A1c
66%
Adverse Event
66%
Antidiabetic Agent
33%
Diabetic Ketoacidosis
33%
Bleeding
16%
Randomized Controlled Trial
16%
Random Effects Model
16%
Breast Cancer
16%
Hypoglycemia
16%
Neuroscience
Hemoglobin A1c
100%
Diabetes Mellitus
50%
Randomized Controlled Trial
25%
Hypoglycemia
25%